Cancer vaccine attenuates carcinogen induced head and neck cancer with impaired early T cell response
M. Kono, M. Rokugo, J. D. Quadarella, S. Saito, H. Komatsuda, C. Fu, S.-B. Woo, A. M. Egloff, R. Uppaluri
This study shows that a cancer vaccine combined with anti-PD-1 therapy reduces tumor burden and improves survival in a head and neck cancer model with impaired T cell responses.
bioRxiv · Jun 26, 2024 · PreprintCancer Biology